search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


De rol van corticosteroiden op de coagulatie en inflammatie bij astma.


- candidate number10432
- NTR NumberNTR3101
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR12-okt-2011
- Secondary IDs3.2.11.021 / 2010-023931-40;  AF / EudraCT number
- Public TitleDe rol van corticosteroiden op de coagulatie en inflammatie bij astma.
- Scientific TitleThe Role of Corticosteroids on Coagulation and inflammation in asthma.
- ACRONYMROCOCO
- hypothesisWe hypothesize that:
1. Patients with mild-moderate and severe asthma have an increased procoagulant activity as compared to healthy controls;
2. Oral corticosteroids activate coagulation in healthy controls and increase the procoagulant activity in mild-moderate and severe asthmatic patients;
3. Increase of hypercoagulation is correlated with asthma severity and use of high dose corticosteroids.
- Healt Condition(s) or Problem(s) studiedAsthma, Inflammation, Coagulation, Corticosteroids
- Inclusion criteriaAll subjects:
1. Age between 18 – 75 years;
2. Non-smoking or stopped smoking more than 12 months ago and 10 pack years or less;
3. Able to give written and dated informed consent prior to any study-specific procedures.

Healthy controls:
1. Baseline FEV1 80% of predicted;
2. Methacholine PC20> 8 mg/ml 29;
3. No usage of steroids by any dosing route;
4. Negative allergy testing by skin prick test or specific IgE;
5. Negative history of pulmonary and any other relevant diseases.

Patients with asthma:
1. All patients have previous evidence of variable airways obstruction within the last 5 years, as documented by at least one of the following:
A. Reversibility in forced expiratory volume in one second (FEV1) of ≥12% predicted after 4 puffs of a 100 µg salbutamol dose-aerosol, administered via a spacer;
B. A mean diurnal variation in peak expiratory flow (PEF) ≥15% (highest PEF - lowest PEF) per mean PEF on ≥4 days per week for a minimum of 2 weeks;
C. An increase in FEV1 of ≥400 mL after a course of prednisolone 0.5 mg•kg−1•day−1 for 14 days;
D. A provocative concentration causing a 20% fall in FEV1 with histamine or methacholine <8 mg/mL.29.
2. Clinically stable, for patients with mild asthma this means no exacerbations within the last 8 weeks prior to the study;
3. No other clinically significant abnormality on history and clinical examination;
4. The use of short and long-acting 2-agonists, leukotriene receptor antagonist, short or long acting anticholinergic agonists are allowed provided that the dose of these drugs remains stable during the study.

Mild/Moderate asthmatic patients:
1. Baseline FEV1 70% of predicted 30;
2. Low- to medium-dose use of inhaled corticosteroids (ICS) (fluticason ≤ 500 μg/day or equivalent drug).

Severe asthmatic patients:
1. Severe asthma according to the recently published consensus criteria of the Innovative Medicine Initiative (IMI)31;
2. High- and ultrahigh dose of ICS (Fluticasone ≥1000 μg/day or equivalent drug);
3. On stable doses of inhaled corticosteroids during the previous 4 weeks and during the study.
- Exclusion criteriaExclusion criteria for all patient-groups are as follows:
1. Women who are pregnant or lactating or who have a positive urine pregnancy test at screening;
2. Participation in any clinical investigational drug treatment protocol within the preceding 30 days;
3. Use of heparin, LMWH, or vitamin K antagonists;
4. Use of omalizumab during the last 6 months before randomization;
5. Use of prednisolone during the last 8 weeks before randomization;
6. Ongoing use of tobacco products of any kind or previous usage with a total pack year ≥ 10 years;
7. General contraindications for the use of corticosteroid use, including a known diagnosis of peptic ulcers, osteoporosis, psychoses, infections, diabetes and hypertension, or symptoms and signs compatible with one of the above diagnoses;
8. Concomitant disease or condition which could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or which would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study;
9. Unwillingness or inability to comply with the study protocol for any other reason.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-nov-2011
- planned closingdate1-mrt-2013
- Target number of participants90
- InterventionsPatients will be randomized to receive either prednisolon (once daily 0,5mg/kg) or identical placebo for 10 days.
- Primary outcomePrimary endpoint will be the change in TATc and PAPc in blood.
- Secondary outcomeSecondary endpoints will be changes in markers of hemostasis and inflammation in blood, induced sputum and exhaled breath.
- TimepointsAt baseline, day 1 and day 11.
- Trial web siteN/A
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESDrs. C.J. Majoor
- CONTACT for SCIENTIFIC QUERIESDrs. C.J. Majoor
- Sponsor/Initiator Academic Medical Center (AMC), Department of Respiratory Medicine , Netherlands Asthma Foundation
- Funding
(Source(s) of Monetary or Material Support)
Netherlands Asthma Foundation, Academic Medical Center (AMC), Department of Respiratory Medicine
- PublicationsN/A
- Brief summaryAsthma is a chronic inflammatory disease of the airways characterised by variable airways obstruction and although asthma can be well controlled in most patients by treatment with inhaled corticosteroids, there is a small subset of patients requiring oral corticosteroids for asthma control. High levels of glucocorticoids, either endogenous or exogenous, have been shown to induce hypercoagulability and an increased risk of venous thromboembolism.
In asthma corticosteroids, either inhaled or oral, have been shown to influence hemostasis. In patients with moderate asthma inhaled corticosteroids decrease the activation of coagulation, while in severe asthmatic patients a further activation of coagulation may occur. Oral corticosteroids further activate coagulation during an acute exacerbation.
In addition, asthma itself has also been associated with a prothrombotic state, and preliminary data from our group have shown an increased risk of pulmonary embolism in patients with severe asthma that was associated with chronic oral corticosteroid use and frequent asthma exacerbations.
Therefore, an activated coagulation system might enhance the inflammatory process in the airways of asthmatics and contribute to therapy resistance in those with severe disease.
- Main changes (audit trail)18-Oct-2012: Planned enddate will now be 01-Jul-2014 - NM
21-Dec-2014: Data collection ended. Last patiëntcontact: 11-Dec-2014. - AB
- RECORD12-okt-2011 - 21-dec-2014


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl